This “Specialty Testing” webinar will discuss the diagnosis, pathological understanding, and current best treatment options for necrotizing autoimmune myopathy.

By MCL Education • January 31, 2019

A movement disorder might be caused by the body’s immune system, which is meant to fight infections, suddenly attacking the brain. Fortunately, an “autoimmune movement disorder” can often be treated—once its cause is discovered.

By Chris Bahnsen • January 17, 2019

Mayo Clinic researchers report that spinal cord inflammation associated with an antibody to myelin oligodendrocyte glycoprotein can mimic acute flaccid myelitis, a rare but serious disease linked to certain viruses that particularly affects children and can result in paralysis.

By Mayo Clinic Advancing the Science • January 17, 2019

Sean Pittock, M.D., and Andrew McKeon, M.B., B.Ch., M.D., were featured in a Post Bulletin series about autoimmune neurology disorders and the research and services that Mayo Clinic offers patients.

By Suzanne Ferguson • December 5, 2018

This week’s Research Roundup highlights the association of apolipoprotein E ε4 with transactive response DNA-binding protein 43.

By Kelley Luedke • November 19, 2018

For patients who have been diagnosed with acute disseminated encephalomyelitis, Mayo researchers have found a direct correlation between a specific antibody, myelin oligodendrocyte glycoprotein—also known as MOG, and an increased risk of recurring attacks in these individuals.

By Gina Chiri-Osmond • November 6, 2018

Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.

By Alyssa Frank • October 25, 2018

This week’s Research Roundup highlights paraneoplastic neuronal intermediate filament autoimmunity.

By Kelley Luedke • October 15, 2018

In 2017, Mayo Clinic launched a first-in-the-U.S. clinical test to help patients with some autoimmune disorders get the right diagnosis faster. The test defines a new form of inflammatory demyelinating disease, called myelin oligodendrocyte glycoprotein autoimmunity, which is distinct from multiple sclerosis, with which it is commonly confused.

By Mayo Clinic Alumni Association • August 31, 2018

Andrew McKeon, M.D., M.B., B.Ch., and Sean J. Pittock, M.D., neurologists and co-directors of the Mayo Clinic Neuroimmunology Laboratory in Rochester, Minnesota, answer questions about Mayo Clinic's new test.

By Mayo Clinic Clinical Updates • August 3, 2018

This "Specialty Testing" webinar will outline the benefits and limitations of genetic testing for neurologic disorders and provide a framework for interpretation of test results.

By MCL Education • July 12, 2018

This week’s Research Roundup highlights potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations.

By Kelley Luedke • May 14, 2018

For people with encephalitis, rapid treatment of their acute brain inflammation is critical for avoiding devastating physical and cognitive deficits. But appropriate treatment requires identifying the culprit causing the symptoms.

By Barbara J. Toman • April 29, 2018